International Assets Investment Management LLC Purchases New Shares in Axonics, Inc. (NASDAQ:AXNX)

International Assets Investment Management LLC bought a new position in Axonics, Inc. (NASDAQ:AXNX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,131 shares of the company's stock, valued at approximately $817,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AXNX. RiverPark Advisors LLC boosted its holdings in shares of Axonics by 14.4% during the fourth quarter. RiverPark Advisors LLC now owns 1,185 shares of the company's stock worth $74,000 after purchasing an additional 149 shares during the period. Arizona State Retirement System raised its position in Axonics by 2.2% during the third quarter. Arizona State Retirement System now owns 14,345 shares of the company's stock valued at $805,000 after acquiring an additional 311 shares in the last quarter. HighMark Wealth Management LLC raised its position in Axonics by 200.0% during the third quarter. HighMark Wealth Management LLC now owns 525 shares of the company's stock valued at $29,000 after acquiring an additional 350 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Axonics by 2.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,846 shares of the company's stock valued at $1,226,000 after acquiring an additional 446 shares in the last quarter. Finally, Hedges Asset Management LLC raised its position in Axonics by 6.5% during the fourth quarter. Hedges Asset Management LLC now owns 8,600 shares of the company's stock valued at $535,000 after acquiring an additional 525 shares in the last quarter. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AXNX has been the topic of several recent research reports. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $71.00 price objective (up previously from $68.00) on shares of Axonics in a research report on Wednesday, January 10th. CL King reissued a "neutral" rating on shares of Axonics in a research report on Friday, January 12th. SVB Leerink reissued a "market perform" rating and issued a $71.00 price target on shares of Axonics in a research report on Friday, January 12th. Truist Financial reissued a "hold" rating and issued a $71.00 price target (down previously from $73.00) on shares of Axonics in a research report on Friday, January 12th. Finally, Wolfe Research lowered shares of Axonics from an "outperform" rating to a "peer perform" rating in a research report on Tuesday, January 9th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Axonics currently has an average rating of "Hold" and an average target price of $70.73.

Axonics Stock Up 0.3 %

AXNX traded up $0.17 during trading on Wednesday, reaching $66.64. 396,114 shares of the company's stock were exchanged, compared to its average volume of 1,271,365. Axonics, Inc. has a fifty-two week low of $47.59 and a fifty-two week high of $69.68. The business has a 50 day moving average price of $67.97 and a 200 day moving average price of $62.65. The company has a market capitalization of $3.40 billion, a P/E ratio of -512.58 and a beta of 0.56.

Axonics (NASDAQ:AXNX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.07. Axonics had a negative net margin of 1.66% and a negative return on equity of 1.00%. The firm had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. During the same quarter in the previous year, the company earned $0.01 earnings per share. The business's revenue was up 27.7% compared to the same quarter last year. As a group, research analysts forecast that Axonics, Inc. will post 0.32 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Raymond W. Cohen sold 35,161 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total value of $2,381,806.14. Following the sale, the chief executive officer now owns 188,835 shares in the company, valued at approximately $12,791,682.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Raymond W. Cohen sold 35,161 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total value of $2,381,806.14. Following the sale, the chief executive officer now owns 188,835 shares in the company, valued at approximately $12,791,682.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karen Noblett sold 11,288 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $764,649.12. Following the completion of the sale, the insider now owns 34,428 shares in the company, valued at approximately $2,332,152.72. The disclosure for this sale can be found here. Insiders have sold 65,837 shares of company stock worth $4,459,798 over the last 90 days. Corporate insiders own 1.85% of the company's stock.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.